Ezh2 inhibitors (Dana-Farber Cancer Institute/Boston Children's Hospital)

N/A

Report date: 2025/01/26 18:00:32
NME

Base Information

Drug NameEzh2 inhibitors (Dana-Farber Cancer Institute/Boston Children's Hospital)
Drug Alias NameJQ5
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone-lysine N-methyltransferase EZH2 degraders
TargetsHistone-lysine N-methyltransferase EZH2
Therapy Area/IndicationsGraft vs Host DiseaseLeukemia, Myelogenous, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesDana-Farber Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteThe Children's Hospital Corp
Inactive CompaniesN/A
Active IndicationsGraft vs Host DiseaseLeukemia, Myelogenous, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A